髓系细胞触发受体-1在眼病发病中的作用

Role of myeloid cell trigger receptor-1 in the pathogenesis of ophthalmopathy

髓系细胞触发受体-1(triggering receptor expressed on myeloid cells-1,TREM-1)属于免疫球蛋白超家族的细胞表面受体,其信号通路参与炎性反应放大,抑制其通路可降低炎症水平。在感染性角膜炎动物模型及临床患者,感染的角膜组织中TREM-1表达较正常角膜均显著增加,其可扩大角膜炎的炎性反应,与炎性介质以及临床炎症评分正相关。而抑制其信号通路则可不同程度降低角膜炎性反应,对角膜炎的临床预后有重要影响。此外,TREM-1在眼弓形虫病、缺血性视神经病变、视网膜新生血管性疾病动物模型的相关组织中表达也明显增加。目前TREM-1阻断剂LR12已进入二期临床试验阶段。

Triggering receptor expressed on myeloid cell-1(TREM-1)is a cell surface receptor belonging to the immunoglobulin superfamily.Its signaling pathway participates in the amplification of inflammatory response,and inhibition of its pathway can reduce inflammation level.In eye diseases,both in animal model and clinical infectious keratitis patients,the expression of TREM-1 in corneal tissues is significantly increased compared with normal cornea,which can expand the inflammatory response of keratitis,and is positively correlated with inflammatory mediators and clinical inflammation scores.Inhibition of its signaling pathway can reduce corneal inflammatory response to varying degrees,affecting the clinical prognosis of keratitis.In addition,the expression of TREM-1 was significantly increased in relevant tissues of animal models of ocular toxoplasmosis,ischemic optic neuropathy and retinal neovascular disease.TREM-1 blocker(LR12)is currently in phase II clinical trials.